ArticleThe journal of prevention of Alzheimer's disease2023
Editorial: Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease.
Article in The journal of prevention of Alzheimer's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Psychological impacts of APOE genotype disclosure among Latinos in New York City: a randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Legal Protections to Mitigate Discrimination due to Neurodegenerative Biomarker Status.Neurology · 2026Review
- Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Toward personalized medicine in AD/ADRD through genetic-exposome dementia risk assessments.NPJ dementia · 2026Review
- Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway.Nature neuroscience · 2024Review
- Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice.Neurology. Clinical practice · 2024Article
- Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.International journal of Alzheimer's disease · 2024Review
- Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2024Article
- The Sigma Receptors in Alzheimer's Disease: New Potential Targets for Diagnosis and Therapy.International journal of molecular sciences · 2023Review
- Preparedness and quality of dementia care in an Italian health authority when introducing anti-Aβ therapies.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.